GCM
PRLD icon

Graham Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Graham Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.8K Buy
+11,343
New +$29.7K ﹤0.01% 1100

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Graham Capital Management's PRLD Position: Q1 2026 in Review

Graham Capital Management opened a new position in Prelude Therapeutics (PRLD) in Q1 2026: 11,343 shares worth $38.8K. The stake represents ﹤0.01% of the portfolio and ranks #1100 among its holdings.

55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Graham Capital Management held 11,343 shares of Prelude Therapeutics worth $38.8K as of Q1 2026.
  • Prelude Therapeutics was a new Graham Capital Management position in Q1 2026.
  • Prelude Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1100 holding.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.